Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer
Jiayi Lin, Haijun Liu, Ye Wu, et al.
Small (2023) Vol. 19, Iss. 18
Closed Access | Times Cited: 16

Showing 16 citing articles:

Nano-PROTACs: state of the art and perspectives
Jie Zhong, Ruiqi Zhao, Yuji Wang, et al.
Nanoscale (2024) Vol. 16, Iss. 9, pp. 4378-4391
Closed Access | Times Cited: 19
Glutathione‐Scavenging Nanoparticle‐Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects
Haijun Liu, Wei Chen, Gongwei Wu, et al.
Advanced Science (2023) Vol. 10, Iss. 16
Open Access | Times Cited: 40
Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges
Xiao-kun Zhang, Ye Wu, Jia-Yi Lin, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 9, pp. 3818-3833
Open Access | Times Cited: 8
New implications for prion diseases therapy and prophylaxis
Fangzhou Liu, Wenqi Lü, Ling Liu
Frontiers in Molecular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 6
Uncovering PROTAC Sensitivity and Efficacy by Multidimensional Proteome Profiling: A Case for STAT3
Yuying Suo, Daohai Du, Chao Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4804-4818
Closed Access | Times Cited: 5
Cancer immunotherapy and its facilitation by nanomedicine
Chao Sui, Heqing Wu, Xinxin Li, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 5
TACkling Cancer by Targeting Selective Protein Degradation
María del Mar Noblejas‐López, David Tébar-García, Raquel López-Rosa, et al.
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2442-2442
Open Access | Times Cited: 11
Autophagy-Activating Nanoautophagosome-Tethering Compounds for Targeted Protein Degradation Specifically in Tumor Cells
Mengchen Xu, Jiajing Chen, Shuyu Wang, et al.
ACS Macro Letters (2025), pp. 250-257
Closed Access
Cascade-responsive nano-PROTACs for tumor-specific ALK protein degradation and enhanced cancer therapy
Yanping Zhao, Junhui Sui, Jian Chang, et al.
Nano Today (2025) Vol. 62, pp. 102693-102693
Closed Access
Cancer Specific CAIX‐Targeting Supramolecular Lysosome‐Targeting Chimeras (Supra‐LYTAC) for Targeted Protein Degradation
Do‐Hyun Kim, Gyeongseok Yang, Chaelyeong Lim, et al.
Advanced Science (2025)
Open Access
Supramolecular artificial Nano-AUTACs enable tumor-specific metabolism protein degradation for synergistic immunotherapy
Yazhen Wang, Lianyi Yang, C. Yan, et al.
Science Advances (2024) Vol. 10, Iss. 25
Open Access | Times Cited: 3
M1/M2 macrophage-targeted nanotechnology and PROTAC for the treatment of atherosclerosis
Yupeng Ma, Xiaofan Yang, Ke Ning, et al.
Life Sciences (2024) Vol. 352, pp. 122811-122811
Open Access | Times Cited: 2
Discovery of X10g as a selective PROTAC degrader of Hsp90α protein for treating breast cancer
Qingna Jiang, Minghai Fu, Yuanling Tang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115690-115690
Closed Access | Times Cited: 6
Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation
Yejin Sung, Seung Taek Hong, Mihue Jang, et al.
Biomaterials (2023) Vol. 303, pp. 122382-122382
Open Access | Times Cited: 6
DNA Nanotechnology for Application in Targeted Protein Degradation
Yang Xiao, Xinyi Guo, Weiwei Zhang, et al.
ACS Biomaterials Science & Engineering (2024) Vol. 10, Iss. 11, pp. 6814-6827
Closed Access
Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics
Wutong Zhao, Yongbin Jiang, Xiufen Li, et al.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology (2024) Vol. 16, Iss. 6
Closed Access
Page 1

Scroll to top